Dapagliflozin Should Be Continued in Dialysis Patients with Heart Failure
Continue dapagliflozin 10 mg daily in your dialysis patient with heart failure, as emerging evidence demonstrates cardiovascular benefits persist even in end-stage kidney disease, and the drug is safe when dialysis is established. This recommendation prioritizes mortality and quality-of-life outcomes over traditional glycemic considerations.
Evidence Supporting Continuation in Dialysis
Cardiovascular Protection Persists at Very Low eGFR
Dapagliflozin reduces cardiovascular death or heart failure hospitalization by 29% even when eGFR falls below 25 mL/min/1.73 m², and this benefit appears to extend to patients approaching or on dialysis 1.
In pooled analysis of DAPA-HF and DELIVER trials, patients who experienced eGFR deterioration to <25 mL/min/1.73 m² showed a 47% relative risk reduction in the primary outcome (HR 0.53,95% CI 0.33–0.83) when continuing dapagliflozin, compared to 22% reduction in those without such deterioration 1.
The benefit-to-risk ratio favors continuation of dapagliflozin in patients with heart failure experiencing severe kidney function deterioration, as safety outcomes remained similar between treatment groups even at eGFR <25 mL/min/1.73 m² 1.
Guideline Support for Continuation
Current guidelines recommend continuing dapagliflozin 10 mg daily even when eGFR falls below 25 mL/min/1.73 m² until dialysis is initiated, based on preserved cardiovascular and mortality benefits 2.
The cardiovascular protective effects of dapagliflozin are independent of residual kidney function, suggesting the mechanism extends beyond renal glucose handling 2, 1.
Ongoing Trial Evidence
The DARE-ESKD-2 trial is actively investigating dapagliflozin's effects on myocardial function in established dialysis patients, with the hypothesis that myocardial benefits persist regardless of residual kidney function 3.
This trial specifically enrolled adults on regular dialysis for more than 3 months, examining NT-proBNP levels, left ventricular function, and functional capacity as primary outcomes 3.
Practical Management Algorithm
Continuation Criteria
Confirm the patient is on a stable dialysis regimen (hemodialysis or peritoneal dialysis) for at least 3 months 3.
Verify heart failure diagnosis through clinical symptoms, elevated natriuretic peptides, or echocardiographic findings 2, 1.
Maintain dapagliflozin 10 mg once daily—no dose adjustment is required for dialysis patients 2.
Safety Monitoring
Assess volume status before each dialysis session, as dapagliflozin's mild diuretic effect may interact with ultrafiltration goals 2.
Monitor for genital mycotic infections (≈6% incidence) and counsel on daily hygiene measures 2.
Watch for euglycemic diabetic ketoacidosis, particularly during intercurrent illness, though risk is lower in non-diabetic patients 2, 4.
Medication Adjustments
Continue ACE inhibitors or ARBs without dose changes when maintaining dapagliflozin, as the combination provides additive cardiovascular protection 2.
Consider reducing loop diuretic doses in peritoneal dialysis patients to prevent excessive volume depletion 2, 5.
If the patient is diabetic and on insulin, reduce insulin doses by ≈20% to mitigate hypoglycemia risk, though glycemic efficacy is minimal on dialysis 2.
Critical Pitfalls to Avoid
Do not discontinue dapagliflozin solely because the patient started dialysis—cardiovascular benefits persist and may be most pronounced in this highest-risk population 1.
Do not expect meaningful glucose-lowering effects—the primary benefit in dialysis patients is cardiovascular protection and improved myocardial function, not glycemic control 2, 3.
Do not withhold dapagliflozin during routine dialysis sessions—only hold during acute illness with reduced oral intake, fever, vomiting, or diarrhea 2.
Do not stop the drug if the patient develops mild volume depletion—adjust ultrafiltration goals and diuretic doses first before considering discontinuation 2, 5.
Contraindications Specific to Dialysis Patients
Pregnancy or breastfeeding remain absolute contraindications 2.
Active Fournier gangrene or recurrent severe genital infections warrant discontinuation 2.
Hemodynamic instability requiring IV vasopressors or inotropes (excluding nitrates) is a temporary contraindication until stabilization 5.
Strength of Evidence
The recommendation to continue dapagliflozin in dialysis patients with heart failure is based on:
High-quality post-hoc analysis from two large randomized controlled trials (DAPA-HF and DELIVER) showing sustained benefit at eGFR <25 mL/min/1.73 m² 1.
Guideline consensus from multiple societies supporting continuation until dialysis initiation, with emerging evidence suggesting benefit may extend beyond this threshold 2.
Ongoing prospective trial (DARE-ESKD-2) specifically designed to evaluate cardiovascular outcomes in established dialysis patients 3.
Consistent cardiovascular mortality reduction (31% in DAPA-CKD) that appears independent of renal function 6, 7.
The evidence hierarchy strongly favors continuation, as the alternative—discontinuing a medication that reduces cardiovascular death by nearly one-third—carries substantially greater risk than any documented safety concern in this population.